Office of Commercialization  Prevention of cancer treatment-related heart toxicity
Prevention of cancer treatment-related heart toxicity

Prevention of cancer treatment-related heart toxicity

Description:

 

Unmet Need: Effective strategies to prevent cancer treatment related cardiotoxicity.

Anthracyclines are currently the cornerstone of many modern chemotherapy regimens. For example, Doxorubicin (DOX, trade name Adriamycin), is frequently used to treat hematological malignancies and solid tumors. Unfortunately, administration of DOX also causes cumulative dose-dependent cardiotoxicity that manifests as cardiomyopathy, which can eventually lead to heart failure and death. These undesired cardiovascular side effects severely limit the clinical use of anthracyclines. Despite the fact that mechanisms of DOX inducing cardiomyocyte apoptosis are known, a widely adopted preventive strategy for DOX cardiotoxicity is currently unavailable Therefore, further investigation of the cardiotoxic mechanisms.

The Technology: Novel drug target for DOX induced cardiotoxicity.

The forkhead box O (FOXO) subfamily protein FOXO1 plays a critical role in cardiac development and pathophysiology. Studies done by the researchers at WSU suggest that FOXO1 mediates DOX-induced cardiomyocyte apoptosis.  Researchers further found a selective small molecule FOXO1 inhibiter which when administered with DOX as a combination, would reduce the risk of treatment related heart toxicity significantly.

Applications:

  • Combination therapeutic drug for Cancer

Advantages:

  • Would reduce the cardiac complications during cancer treatment.
  • Would allow doctors to effectively utilize the anti-cancer drugs and have minimal side effects.

 

Patent Information: